Top Markets
#1 Pons Pons +10.72%
#2 StonkBroker StonkBroker +7.70%
#3 龙虾 (Lobster) 龙虾 (Lobster) +7.11%
#4 Siacoin Siacoin +6.63%
#5 Story Story +5.66%
#6 Cash Cat Cash Cat +5.40%
#7 Unit Pump Unit Pump +4.76%
#8 Pump.fun Pump.fun +4.76%
#9 Status Status +4.75%
#10 Seeker Seeker +4.04%
Coin of the day
Pons Pons
Inställningar
Språk
SVENSKA
Valuta
USD
Tema
Q32 Bio Inc. Q32 Bio Inc.

Q32 Bio Inc.

QTTB
Rankning i aktier #14023
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to... Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Aktiekurs
$14.86
Senast synkroniserad: 2026-08-31
Marknadsvärde
$442.29M
Förändring (1 dag)
-1.13%
Förändring (1 år)
769.01%
Land
US
Handel Q32 Bio Inc. (QTTB)

Kategori

Healthcare
Utdelningsavkastning för Q32 Bio Inc. (QTTB)
Utdelningsavkastningen (TTM) för Q32 Bio Inc. (aktiesymbol: QTTB) per 2026 är: 0
Genomsnittlig utdelningsavkastning de senaste 5 åren: 0.00%
Historik för utdelningsavkastning för Q32 Bio Inc. (QTTB) från 2026 till 2026
Utdelningsavkastning i slutet av varje år (TTM)
År Utdelningsavkastning Ändra
Inte tillräckligt med data för de angivna datumen.
Utdelningsavkastning (TTM) för liknande företag eller konkurrenter
Företag Utdelningsavkastning Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.12%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH